Media stories about Aimmune Therapeutics (NASDAQ:AIMT) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aimmune Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.183168148361 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- How Trading Notes Can Increase Your Profits (finance.yahoo.com)
- Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy (finance.yahoo.com)
- Aimmune Therapeutics, Inc. (NASDAQ:AIMT): Going Behind the Numbers – Clawson News (clawsonnews.com)
- Aimmune Therapeutics (AIMT) Releases 2018 Outlook; Announces Upcoming Data from Pivotal Phase 3 PALISADE … – StreetInsider.com (streetinsider.com)
- Aimmune Therapeutics (AIMT) Downgraded by Zacks Investment Research (americanbankingnews.com)
Shares of Aimmune Therapeutics (AIMT) traded up $0.78 during trading hours on Friday, hitting $39.43. The company had a trading volume of 370,464 shares, compared to its average volume of 405,663. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $40.00. The stock has a market capitalization of $2,010.00 and a price-to-earnings ratio of -16.85.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts anticipate that Aimmune Therapeutics will post -2.51 EPS for the current year.
AIMT has been the topic of several research analyst reports. Credit Suisse Group lifted their price target on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Roth Capital began coverage on Aimmune Therapeutics in a research note on Monday, November 20th. They set a “buy” rating and a $60.00 price objective for the company. Piper Jaffray Companies raised their price objective on Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 5th. Finally, Wedbush reissued an “outperform” rating and set a $70.00 price objective (up from $42.00) on shares of Aimmune Therapeutics in a research note on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $55.43.
In other Aimmune Therapeutics news, insider Daniel C. Md Adelman sold 3,283 shares of the firm’s stock in a transaction dated Thursday, December 27th. The stock was sold at an average price of $40.00, for a total transaction of $131,320.00. Following the transaction, the insider now directly owns 3,283 shares in the company, valued at $131,320. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Stephen George Dilly sold 1,154 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $26.24, for a total value of $30,280.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 137,946 shares of company stock valued at $4,991,189. 24.56% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.thelincolnianonline.com/2018/01/13/aimmune-therapeutics-aimt-earns-daily-media-impact-rating-of-0-14-updated-updated.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.